Insider · CIK 0001689739
Edward Pershing
ceoofficerdirectorowner
Files at PVCT (PROVECTUS BIOPHARMACEUTICALS, INC.). First filing -, latest -.
In brief
Edward Pershing files SEC Form 4 as CEO, director and 10% owner at PVCT (PROVECTUS BIOPHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Edward Pershing has 0, so none is measured yet.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
The newest 50 of 109 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 3, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | 8 d ago |
| Oct 3, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +13,216 | $0.00 | $0 | 2,975,925 | 8 d ago |
| Sep 18, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | 25 d ago |
| Sep 18, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +13,216 | $0.00 | $0 | 2,962,709 | 25 d ago |
| Sep 11, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | 32 d ago |
| Sep 11, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +13,216 | $0.00 | $0 | 2,949,493 | 32 d ago |
| Sep 4, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | 35 d ago |
| Sep 4, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +11,328 | $0.00 | $0 | 2,936,277 | 35 d ago |
| Aug 26, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Aug 26, 2026 |
| Aug 26, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +11,328 | $0.00 | $0 | 2,924,949 | Aug 26, 2026 |
| Jun 30, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award Series D-1 Convertible Preferred Stockderivative | +45,860 | $0.00 | $0 | 2,866,761 | Jul 2, 2026 |
| Jun 5, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Jun 5, 2026 |
| Jun 5, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +9,436 | $0.00 | $0 | 2,857,285 | Jun 5, 2026 |
| May 28, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | May 29, 2026 |
| May 23, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | May 26, 2026 |
| May 23, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +32,089 | $0.00 | $0 | 2,847,849 | May 26, 2026 |
| May 15, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | May 15, 2026 |
| May 15, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +22,651 | $0.00 | $0 | 2,815,760 | May 15, 2026 |
| May 7, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | May 7, 2026 |
| May 7, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +18,876 | $0.00 | $0 | 2,793,109 | May 7, 2026 |
| Apr 29, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Apr 29, 2026 |
| Apr 29, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +30,202 | $0.00 | $0 | 2,774,233 | Apr 29, 2026 |
| Apr 4, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Apr 6, 2026 |
| Apr 4, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +33,977 | $0.00 | $0 | 2,744,031 | Apr 6, 2026 |
| Mar 25, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Mar 26, 2026 |
| Mar 20, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Mar 20, 2026 |
| Mar 20, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +49,067 | $0.00 | $0 | 2,710,054 | Mar 20, 2026 |
| Mar 12, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Mar 16, 2026 |
| Mar 5, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Mar 6, 2026 |
| Feb 26, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Feb 27, 2026 |
| Feb 19, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Feb 23, 2026 |
| Feb 20, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Feb 23, 2026 |
| Feb 20, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +47,180 | $0.00 | $0 | 2,660,987 | Feb 23, 2026 |
| Feb 12, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Feb 17, 2026 |
| Feb 9, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | POpen-market purchase Series D-1 Convertible Preferred Stockderivative | +34,940 | $2.86 | $100k | 2,613,807 | Feb 11, 2026 |
| Feb 5, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Feb 9, 2026 |
| Jan 30, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Feb 2, 2026 |
| Jan 30, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +37,744 | $0.00 | $0 | 2,578,867 | Feb 2, 2026 |
| Jan 28, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Jan 29, 2026 |
| Jan 16, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Jan 16, 2026 |
| Jan 16, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise Series D-1 Convertible Preferred Stockderivative | +37,744 | $0.00 | $0 | 2,541,123 | Jan 16, 2026 |
| Dec 11, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Dec 15, 2025 |
| Dec 5, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Dec 8, 2025 |
| Nov 26, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Nov 28, 2025 |
| Nov 20, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Nov 21, 2025 |
| Nov 13, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Nov 14, 2025 |
| Nov 6, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Nov 7, 2025 |
| Oct 30, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Oct 31, 2025 |
| Oct 23, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Oct 24, 2025 |
| Oct 16, 2025 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | MOption exercise 8% Unsecured Convertible Promissory Notederivative | - | $0.00 | - | - | Oct 17, 2025 |
50 of 109 rows shown.
Questions about Edward Pershing
Answered from the filings on this page, as of the latest one.
Is Edward Pershing buying or selling?
Edward Pershing has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Edward Pershing's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Edward Pershing has 0.
Where does Edward Pershing file Form 4?
Edward Pershing has filed Form 4 at PVCT (PROVECTUS BIOPHARMACEUTICALS, INC.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.